TP53

Overview

TP53 is a protein-coding gene located on the short arm of human chromosome 17 that encodes the tumor suppressor p53, one of the most extensively studied proteins in cancer biology. The p53 protein is a sequence-specific transcription factor that acts as a central node in the cellular response to genotoxic stress, oncogenic signaling, oxidative stress, and metabolic disruption. When activated, p53 induces a transcriptional program governing cell cycle arrest, apoptosis, DNA repair, cellular senescence, and ferroptosis. Canonical p53 target genes include the cyclin-dependent kinase inhibitor p21 (CDKN1A), which enforces cell cycle arrest, and pro-apoptotic effectors such as Bax and PUMA (BBC3). p53 activity is tightly restrained by post-translational regulation, most prominently ubiquitin-mediated degradation by the E3 ligase Mouse Double Minute 2 (MDM2), along with phosphorylation and acetylation events involving regulators such as Sirtuin 1 (SIRT1) and histone deacetylases. Because p53 transcriptionally activates MDM2, the two form a negative feedback loop that sets the amplitude and duration of the p53 response. Upstream signaling through the PTEN/AKT axis, reactive oxygen species, and DNA damage sensors such as PARP1 converges on p53 to determine cell fate.

Somatic mutations in TP53 are found across a wide spectrum of human malignancies, making it among the most frequently altered genes in cancer; these variants are classified as loss-of-function, dominant-negative, or gain-of-function, and many destabilize the DNA-binding domain and abolish wild-type transcriptional activity. Germline TP53 mutations cause Li-Fraumeni syndrome, a hereditary predisposition to early-onset and multiple primary Cancers, and TP53 status is routinely assessed alongside other driver alterations such as KRAS, BRAF, HER2, ALK, and BRCA1 in clinical tumor sequencing and molecular tumor board decision-making. Loss of TP53 also cooperates with other oncogenic events in tumor progression, including in rare pediatric liver sarcomas driven by the C19MC miRNA cluster. Therapeutically, TP53 status shapes response to DNA-damaging agents such as doxorubicin and to targeted drugs including PARP inhibitors like olaparib, and tumors retaining wild-type p53 are candidates for pharmacologic reactivation of the pathway through MDM2 inhibitors and MDM2-targeted degraders. Beyond oncology, p53 signaling contributes to cellular cellular senescence, inflammation via the cGAS/STING pathway, and metabolic and wound-healing pathology, as reflected in its role in macrophage cellular senescence in chronic conditions such as diabetic foot ulcers.

Recent Publications Summary (latest 30 papers)

TP53 status serves as a critical determinant of cancer prognosis and therapeutic response across multiple malignancies. TP53 mutations were identified as a strongly selected event during cytotoxic cancer treatment through therapeutic bottleneck mechanisms, and patients with positively selected TP53 mutations during treatment exhibited the shortest progression-free and overall survival 42262879Jun. In non-muscle-invasive bladder cancer, an integrated molecular classification system identified a distinct cluster (IMC4) predominantly characterized by TP53 alterations with differential treatment responses 42142129May. TP53 mutations also define prognostically significant subsets in myelodysplastic syndromes and acute myeloid leukemia, including cases with complex karyotypes and unique inflammatory manifestations 42067682May. Spatial biomarker discovery platforms have identified histopathological features predictive of TP53 mutations across large colorectal cancer cohorts, enabling precision prognostication 42276049Jun.

TP53 wild-type tumors demonstrate enhanced sensitivity to therapeutic strategies that engage p53 pathway activation. A selective CK1α degrader (PinA1) induced enhanced p53 expression, cell-cycle arrest, and apoptosis specifically in TP53 wild-type acute myeloid leukemia cell lines and primary patient samples, with minimal effects on normal hematopoietic cells and synergistic activity when combined with FLT3, BCL-2, or MDM2 inhibitors 42545171Aug. MDM2 degraders (KTX-049 and KT-253) overcame p53/MDM2 negative feedback inhibition and demonstrated superior potency compared to MDM2 inhibitors in wild-type TP53 Merkel cell carcinoma, with acquired resistance consistently associated with TP53 mutations 42383359Jul. Multiple small-molecule and natural product compounds activate p53-dependent apoptotic pathways: 4-chloro-7-nitrobenzofurazan induced ROS-mediated p53-dependent apoptosis in fibrosarcoma 42429843Jul; Carissa macrocarpa and Artemisia monosperma extracts upregulated p53 and apoptosis-related genes in colorectal cancer cells 42114831May42069779May; and a GLUT inhibitor (MF48) suppressed glucose transporters to activate the p53/p21/caspase-3 apoptotic pathway in colorectal cancer 42315971Jun. A traditional Chinese medicine formula (Xin Jia Congrong Tusizi Decoction) reversed ferroptosis in granulosa cells via p53/Nrf2/SLC7A11/GPX4 pathway activation 42000005Apr.

TP53 mutations present opportunities for targeted reactivation and functional screening approaches. In vitro screening identified AG3, a compound combining zinc chelation with Michael acceptor functionality, which reactivated the thermodynamically unstable Y220C p53 mutation in gastric cancer cells, induced p53-dependent cytotoxicity, and enhanced chemotherapy responses while limiting toxicity to normal cells 42163716May. Prime editing technology enabled high-throughput functional screening of TP53 variants using pegRNA-free virus-like particle delivery; a 6,000-pegRNA library targeting TP53 identified loss-of-function variants conferring Nutlin-3 resistance with 2.8-fold higher editing efficiency and improved reproducibility compared to conventional lentiviral approaches 42447864Jul. The PREMIER platform, employing prime editing with microhomology-enabled replacement of large DNA segments, achieved efficient integration of genomic cassettes in mouse liver and represents a generalizable approach for TP53-directed genomic engineering 42328791Jun.

TP53 alterations define disease-specific therapeutic vulnerabilities and resistance mechanisms across cancer subtypes. TP53-mutated acute myeloid leukemia with recurrent deletions encompassing ribosomal protein genes (del(3p) and del(5q)) exhibited a ribosomopathy-like phenotype with reduced protein synthesis conferring selective vulnerability to HSP90 inhibition 42139355May. In B-cell acute lymphoblastic leukemia, TP53 inactivation emerged as a driver of chimeric antigen receptor T-cell resistance through FATP2-mediated fatty acid uptake and oxidation pathways, with vulnerabilities targetable through lipid metabolism inhibition 42380664Jul. Stepwise malignant transformation from mesenchymal hamartoma to undifferentiated embryonal sarcoma of the liver required synergistic cooperation between C19MC miRNA cluster activation and TP53 loss, establishing TP53 loss-of-function as an essential secondary event in hepatic malignant progression 42448860Jul.

What Changes, What Holds

1. TP53 mutations selected during cytotoxic therapy confer the shortest survival -- NEW DIRECTION

TP53 alterations emerge as strongly selected resistance events during cytotoxic treatment, not passive pre-existing alterations. Patients whose tumors harbor positively selected TP53 mutations during therapy exhibit the shortest progression-free and overall survival, identifying TP53 mutation emergence as a therapeutic bottleneck marking treatment failure 42262879Jun. The Overview addresses how baseline TP53 status determines initial treatment response but does not cover the evolution of TP53 mutations as acquired resistance or their role as prognostic markers of rapid progression.

2. Multiple mechanistic pathways reactivate wild-type p53 beyond canonical MDM2 targeting -- REINFORCES

CK1α degraders, natural product extracts, and glucose metabolism inhibitors activate wild-type p53 through diverse mechanisms—phosphorylation cascades, ROS generation, and metabolic stress—alongside established MDM2 inhibitors and degraders 42545171Aug42114831May42315971Jun. This confirms the therapeutic axiom that wild-type p53 remains a tractable target while expanding the mechanistic and pharmacological toolkit. MDM2 degraders demonstrate superior potency by overcoming the negative feedback loop, mechanistically validating their advancement over inhibitors 42383359Jul. The Overview already identifies wild-type TP53 tumors as candidates for pathway reactivation; recent work deepens this with additional compounds and mechanisms.

3. Allele-specific restoration of thermolabile mutations expands p53 reactivation beyond wild-type forms -- NEW DIRECTION

AG3, combining zinc chelation with Michael acceptor functionality, reactivates the thermodynamically destabilized Y220C variant and restores p53-dependent cytotoxicity, directly overturning the premise that loss-of-function mutations are pharmacologically intractable 42163716May. This challenges the therapeutic scope the Overview establishes, which restricts reactivation strategies to wild-type TP53 tumors and leaves mutant variants classified solely as liabilities. Extending p53 reactivation to select loss-of-function alleles substantially expands the eligible patient population and argues for allele-specific structural approaches to restore function in destabilized variants.

4. TP53 alterations define cancer subtype-specific metabolic and synthetic lethal vulnerabilities -- NEW DIRECTION

TP53-mutated acute myeloid leukemia with ribosomal protein deletions exhibits a ribosomopathy phenotype vulnerable to HSP90 inhibition, while TP53 inactivation in B-cell acute lymphoblastic leukemia drives CAR-T resistance through FATP2-dependent lipid metabolism, uncovering targetable dependencies 42139355May42380664Jul. These disease-defined vulnerabilities—distinct from the Overview's account of TP53 as a general tumor suppressor determining chemotherapy response—reveal how specific mutational contexts create exploitable metabolic or proteomic liabilities. The Overview covers TP53 cooperation with other oncogenic events but not the resistance mechanisms and synthetic vulnerabilities emerging in particular leukemic and immune contexts.

Overview update candidates: Acquired TP53 mutations as a therapeutic bottleneck and acquired-resistance marker during cytotoxic therapy; allele-specific p53 reactivation as an emerging therapeutic opportunity in loss-of-function variants; subtype-specific metabolic and immune vulnerabilities in TP53-altered leukemias.